⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

AbbVie removed its pandemic-specific risk disclosure from the 2025 10-K, reflecting a shift away from COVID-19 as a material operational concern. The company substantively modified four existing risks, including its R&D development risk, manufacturing process risk, and competitive innovation risk, suggesting refined disclosure language around persistent operational challenges rather than emergence of new risk categories. With 26 risks remaining unchanged and no new risks added, AbbVie's 2025 risk profile demonstrates continuity in its core business vulnerabilities while deprioritizing pandemic-related exposures.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🔴 No Match in Current Filing Public health outbreaks, epidemics or pandemics, such as the coronavirus (COVID-19), have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition. 🔒

🟡 Modified AbbVie's research and development efforts may not succeed in developing products and technologies that can be successfully commercialized, which may cause its revenues and profitability to decline. 🔒

🟡 Modified The manufacture of many of AbbVie's products is a highly exacting and complex process requiring critical environmental controls, and if AbbVie or one of its suppliers encounters problems manufacturing AbbVie's products, AbbVie's business could suffer. 🔒

🟡 Modified New products and technological advances by AbbVie's competitors may negatively affect AbbVie's results of operations. 🔒

🟡 Modified AbbVie depends on information technology and a failure of, or significant disruption to, those systems, or a failure to adequately adopt emerging technologies such as artificial intelligence, could have a material adverse effect on AbbVie's business. 🔒

5 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →